Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

(2018) Hillel P. Cohen et al.   DRUGS

The nocebo effect challenges the non-medical infliximab switch in practice

(2018) N. W. Boone et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review

(2018) Javier P. Gisbert et al.   Gastroenterologia y Hepatologia

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease

(2017) Federico Argüelles-Arias et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

The PROSIT-BIO Cohort

(2017) Gionata Fiorino et al.   INFLAMMATORY BOWEL DISEASES

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany

(2017) Emma Sullivan et al.   PLoS One

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

(2014) Yun-Seong Kang et al.   DIGESTIVE DISEASES AND SCIENCES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

(2008) James D. Lewis et al.   INFLAMMATORY BOWEL DISEASES

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS